Spots Global Cancer Trial Database for bgj398
Every month we try and update this database with for bgj398 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph Ib/BGJ398/Cervix and Other Solid Tumors | NCT02312804 | Cancer of Cervi... Tumors | BGJ398 Carboplatin Paclitaxel | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | NCT01975701 | Recurrent Gliob... | BGJ398 | 18 Years - | Novartis | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | NCT02159066 | Melanoma | LGX818 MEK162 LEE011 BGJ398 BKM120 INC280 | 18 Years - | Pfizer | |
| Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
| A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | NCT01004224 | Advanced Solid ... Squamous Lung C... Bladder Cancer ... Advanced Solid ... Advanced Solid ... Advanced Solid ... | BGJ398 | 18 Years - | Novartis | |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors | NCT02312804 | Cancer of Cervi... Tumors | BGJ398 Carboplatin Paclitaxel | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | NCT02706691 | FGFR Gene Ampli... FGFR1 Gene Ampl... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR3 Gene Muta... Head and Neck S... Human Papilloma... Recurrent Head ... Recurrent Nasop... Recurrent Oroph... | BGJ398 | 18 Years - | University of Chicago | |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | NCT01928459 | Advanced Solid ... Metastatic Soli... | BGJ398 BYL719 | 18 Years - | Novartis | |
| Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | NCT04197986 | Upper Tract Uro... Urothelial Blad... | Infigratinib Placebo | 18 Years - | QED Therapeutics, Inc. | |
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations | NCT02160041 | Solid Tumor Hematologic Mal... | BGJ398 | 18 Years - | Novartis | |
| BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | NCT02257541 | Advanced Gastro... | BGJ398 Imatinib Mesyla... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of Oral BGJ398 in Asian Patients | NCT01697605 | Tumor With Alte... | BGJ398 | 18 Years - | Novartis | |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors | NCT02312804 | Cancer of Cervi... Tumors | BGJ398 Carboplatin Paclitaxel | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | NCT01975701 | Recurrent Gliob... | BGJ398 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
